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NEWS AND PERSPECTIVES
Mutation of Mycobacterium tuberculosis in resis-
tance to tuberculosis drugs occurs spontaneously
and at random,1 but clinically relevant drug resis-
tance is associated with antituberculosis treatment,
appears by selective multiplication of resistant
mutants during treatment (acquired resistance),
and by transmission of drug-resistant organisms
(primary resistance). Proper use of antituberculo-
sis drugs is essential in preventing drug resistance
in tuberculosis. The prevalence and trend of drug
resistance in tuberculosis is an important indicator
of the quality of tuberculosis services.2–8
In 1994, the World Health Organization and
the International Union Against Tuberculosis
and Lung Disease launched the Global Project on
Antituberculosis Drug Resistance Surveillance. The
objectives of the Global Project are to measure
the prevalence of antituberculosis drug resis-
tance worldwide using a standardized methodol-
ogy, to monitor the trend of drug resistance, to
study the correlation between the level of drug
resistance and treatment policies in different set-
tings, and to evaluate the efficiency of treatment
programs.9 To date, four global reports on antitu-
berculosis drug resistance in the world have been
published.2–5
Guidelines for surveillance of drug resistance in
tuberculosis emphasize the following principles:9
1. The sample of specimens should be repre-
sentative of the tuberculosis patients in the
country/geographical setting under study and
the sample size should be determined to per-
mit standard epidemiologic analysis.
2. The patient’s history should be carefully ob-
tained to determine whether or not the patient
has previously received antituberculosis drugs,
which is essential to distinguish between drug
resistance among new cases and that among
previously treated cases.
3. Optimal laboratory performance should be
ensured and maintained through links with a
supranational reference laboratory.
Several facility-based surveys on drug resistance
in tuberculosis in Taiwan were published in past
decades.10–19 These reports indicated the impor-
tance of and the interest in this subject. However,
the findings of these facility-based investigations
cannot be generalized to the overall population
of tuberculosis patients with certainty and have a
limited role in monitoring the trend of drug re-
sistance in tuberculosis. Surveys undertaken with
a nationwide representative sample may be more
widely applicable. An article, published in the
March 2008 issue of this journal, which reported
increasing drug resistance of M. tuberculosis in a
medical center in northern Taiwan highlighted
the problems.18
Su et al18 reported the prevalence of drug resis-
tance in a total of 611 non-duplicate M. tuberculosis
isolates from culture-proven tuberculosis cases
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enrolled in a medical center in Taipei. The prev-
alence of any drug resistance among new and
previously treated cases was as high as 55.1%
and 61.4%, respectively, while that of mono-
resistance to pyrazinamide (PZA) was 8.0% and
11.4%, respectively, and that of resistance to at
least isoniazid and rifampin (multidrug-resistant
tuberculosis [MDR-TB]) was 26.7% and 33.0%,
respectively. There were significant increases in
any resistance as well as MDR-TB in 2003–2004
as compared with their previous report for the
period 1990–1992 in the same hospital. While
the increase in the prevalence of drug resistance
in the medical center is alarming, the findings 
reported need further elaboration.
First, the prevalence of drug resistance (espe-
cially MDR-TB) among previously treated cases
in most settings is substantially higher than that
among new cases. Misclassification of previously
treated tuberculosis cases as new cases would re-
sult in a high prevalence of drug resistance among
new cases. According to The Fourth Global Report,5
the prevalence of MDR-TB among new tubercu-
losis patients ranged from 0% in Andorra, Cuba,
Luxembourg, Malta, Slovenia, Aragon, Spain, and
Uruguay to 22.3% in Baku and Azerbaijan. If there
was no misclassification of previously treated 
tuberculosis cases as new cases in Su et al’s re-
port,18 then the prevalence of MDR-TB among
new patients treated in their medical center would
be the highest in the world, which is unlikely to
be the case.
Second, the number of previously treated tu-
berculosis cases in most drug resistance surveys
is considerably less than that of new cases and
thus is prone to bias in sampling.2–5 Patients 
visiting a tertiary medical center is more likely 
to have been treated with antituberculosis drugs,
and the prevalence of drug resistance among 
previously treated tuberculosis cases in a tertiary
medical center is likely to be higher than that 
observed at the primary health care level because 
of referral of difficult cases from the latter to 
the former. The closure in late 2002 of the
Chronic Disease Control Bureau, a referral center
that specialized in the treatment of drug-resistant
tuberculosis cases in Taipei, probably resulted in
an increase in the number of referrals of previ-
ously treated tuberculosis cases to tertiary med-
ical centers in Taipei, partly contributing to the
increase in drug resistance in 2003–2004 in Su 
et al’s medical center.18 As they correctly point
out, the prevalence of drug resistance among pre-
viously treated cases in their medical center is
not representative of that in Taiwan overall,
which could be obtained in a population-based
study. Further, it would be more informative to
stratify previously treated tuberculosis cases into
the categories of relapse, treatment after default,
and treatment after failure.9,19
Third, PZA susceptibility testing is not recom-
mended on 7H11 agar medium because of poor
reliability.20 Performing PZA susceptibility test-
ing on 7H11 agar may explain a substantial pro-
portion of the PZA monoresistance in Su et al’s
report.
Finally, the quality of susceptibility testing is
an important issue. Five rounds of international
proficiency testing revealed a high degree of agree-
ment of the testing of isoniazid and rifampin
among supranational reference laboratories, but
substantial discordant results for streptomycin and
ethambutol were identified. It also showed that
regular proficiency testing can significantly im-
prove the quality of drug susceptibility testing.21
Since 2006, the Reference Laboratory of Myco-
bacteriology of Taiwan has undertaken proficiency
testing in several laboratories that perform sus-
ceptibility testing of tuberculosis, which has re-
vealed considerable variation in performance with
unsatisfactory results in some laboratories (Ruwen
Jou and colleagues, from the Reference Laboratory
of Mycobacteriology, Research and Diagnostic
Center, Centers for Disease Control, Department
of Health, Executive Yuan, Taiwan; manuscript
submitted).
In conclusion, obtaining a representative sam-
ple of M. tuberculosis isolates from the commu-
nity and ensuring the quality of susceptibility
testing are crucial in the surveillance of drug 
resistance in tuberculosis. It is essential to moni-
tor antituberculosis drug resistance in the fight
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against tuberculosis, and, almost without excep-
tion, the responsibility of ensuring proper surveil-
lance of antituberculosis drug resistance belongs
to the national tuberculosis program.
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